biOasis Technologies Ord Shs V.BTI.H

RE:RE:RE:RE:RE:RE:RE:RE:BiOasis Vs Annexon!

[prophetoffactz]

",,,I am doubtful as well,,,,not sure how she will do it but I certainly think DrDR has some options in the wings to get what meets the objectives. And those options probably need the other side of the table to decide and move. Something she doesnt control."

BTI said the burn rate could consume the cash in about one month. Now we are about 50% past one month. They are waiting for some kind of development(s). A small financing or best efforts offering would have been announced by now. 

There are many poential developments of significance on deck that can help address the financial risk, and help set valuations on assets for which there is currently no commitment to further develop.

Rathjen said multiple parties were interested in xB3-001. That means she could set the date when a decision is made by the parties and if one party doesn't act they could be left behind. A bidding war is ideal for an asset and it is a substantial opportunity. A bidding war for a substantial opportunity with significant valuation can lead to surprises. 

Given BTI's focus all cancer applications may be on the block. The total addressable market for cancer applications is substantial.

The J&J option also expires in January, at the latest, and is for multiple products. The option has an expiry. J&J is a gold plate company. A deal with a gold plate company for multiple products could be substantial.

The Daiichi collaboration expired some moths ago and we don't know what happened. Daiichi is a gold plate company and Herceptin is of interest.

Neuremedy has an option to buy a commercial license. I don't know when the option expires. Option exercise is a commitment to move the product forward after evaluation and can involve cash. BTI could theoretically monitize this asset for upfront cash so as not to have to dilute the company's assets more generally.

The Oxyrane collaboration has been in development for over one year and could be ready for the next step soon. The formalization of a deal could help place a valuation on the project and have implications. A cash payment could be received. A timeline for clinical development could be announced. Currently its just a collaboration.    

The Aposense collaboration is 1 1/2 years old. Collaborations could result in deals and RNAi is a platform technology applicable to many diseases. There has been considerable interest in RNAi and the brain. A platform deal could be significant.

The initiation of the GBS trial appears expected in the next few months on the presentation. The NASDAQ listing was expected not long after. The lack of cash and the NASDAQ listing expectations suggest we are close to something happening. NASDAQ signals important valuation will have been realized.

Chiesi expects to file for FDA approval very soon for Fabry. European and FDA approval is expected in the first half of 2023. Having an approved product may clear the way for the next steps with xB3. Fabry is a US$2.1 billion market and Chiesi could have the standard of care. That heightens the importance of BTI's partner in LSDs and increases the strategic importance of BTI to Chiesi. Protalix also has a Gaucher's enzyme. Perhaps it is in competition with Oxyrane. Chiesis' FDA approval for Fabry in the first half of 2023 is important for Protalix. So is the imminent filing for approval. Does BTI want to commit to an unproven Oxyrane or a proven Protalix.

With multiple opportunities before potential key catalysts with large addressable markets, interest from gold plate companies, and potential bidding wars, and Saltarelli's continied decision to stay with BTI we could see a Saltarelli. He likes world class science and has been with a number of world class companies. He didn't have to stay and should have some indication if BTI is on track to world class. He's said BTI should be able to do what Denali can and we all know the valuation discrepancy between BTI and Denali.